SEARCH

SEARCH BY CITATION

References

  • 1
    Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004; 24 (Suppl. 1): 310.
  • 2
    Moradpour D, Blum HE. A primer on the molecular virology of hepatitis C. Liver Int 2004; 24 (6): 51925.
  • 3
    Geller SA. Hepatitis B and hepatitis C. Clin Liver Dis 2002; 6 (2): 31734, v.
  • 4
    Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006; 25 (27): 383447.
  • 5
    Kanzler S, Galle PR. Apoptosis and the liver. Semin Cancer Biol 2000; 10 (3): 17384.
  • 6
    Schuchmann M, Galle PR. Apoptosis in liver disease. Eur J Gastroenterol Hepatol 2001; 13 (7): 78590.
  • 7
    Galle PR, Hofmann WJ, Walczak H, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182 (5): 122330.
  • 8
    Schmitz I, Kirchhoff S, Krammer PH. Regulation of death receptor-mediated apoptosis pathways. Int J Biochem Cell Biol 2000; 32 (11–12): 112336.
  • 9
    Hayashi N, Mita E. Involvement of Fas system-mediated apoptosis in pathogenesis of viral hepatitis. J Viral Hepat 1999; 6 (5): 35765.
  • 10
    Bantel H, Lugering A, Poremba C, et al. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 2001; 34 (4 Pt 1): 75867.
  • 11
    Gholson CF, Morgan K, Catinis G, et al. Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study. Am J Gastroenterol 1997; 92 (10): 178892.
  • 12
    Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 2960.
  • 13
    Golden-Mason L, Rosen HR. Natural killer cells: primary target for hepatitis C virus immune evasion strategies? Liver Transpl 2006; 12 (3): 36372.
  • 14
    Crotta S, Stilla A, Wack A, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002; 195 (1): 3541.
  • 15
    Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002; 195 (1): 439.
  • 16
    Herzer K, Falk CS, Encke J, et al. Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J Virol 2003; 77 (15): 8299309.
  • 17
    Moriyama T, Guilhot S, Klopchin K, et al. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 1990; 248 (4953): 3614.
  • 18
    Ando K, Moriyama T, Guidotti LG, et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 1993; 178 (5): 154154.
  • 19
    Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77 (1): 6876.
  • 20
    Neumann-Haefelin C, Blum HE, Chisari FV, et al. T cell response in hepatitis C virus infection. J Clin Virol 2005; 32 (2): 7585.
  • 21
    Nakamoto Y, Guidotti LG, Pasquetto V, et al. Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice. J Immunol 1997; 158 (12): 56927.
  • 22
    Hiramatsu N, Hayashi N, Katayama K, et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994; 19 (6): 13549.
  • 23
    Mita E, Hayashi N, Iio S, et al. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun 1994; 204 (2): 46874.
  • 24
    Ando K, Hiroishi K, Kaneko T, et al. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol 1997; 158 (11): 528391.
  • 25
    Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L, et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med 1994; 179 (3): 8418.
  • 26
    Tokushige K, Yamaguchi N, Ikeda I, et al. Significance of soluble TNF receptor-I in acute-type fulminant hepatitis. Am J Gastroenterol 2000; 95 (8): 20406.
    Direct Link:
  • 27
    Sedger LM, Shows DM, Blanton RA, et al. IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol 1999; 163 (2): 9206.
  • 28
    Mundt B, Kuhnel F, Zender L, et al. Involvement of TRAIL and its receptors in viral hepatitis. Faseb J 2003; 17 (1): 946.
  • 29
    Giannini C, Brechot C. Hepatitis C virus biology. Cell Death Differ 2003; 10 (Suppl. 1): S2738.
  • 30
    Zhu N, Khoshnan A, Schneider R, et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 1998; 72 (5): 36917.
  • 31
    Matsumoto M, Hsieh TY, Zhu N, et al. Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor. J Virol 1997; 71 (2): 13019.
  • 32
    Saito K, Meyer K, Warner R, et al. Hepatitis C virus core protein inhibits tumor necrosis factor alpha-mediated apoptosis by a protective effect involving cellular FLICE inhibitory protein. J Virol 2006; 80 (9): 43729.
  • 33
    Herzer K, Weyer S, Krammer PH, et al. Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells. Cancer Res 2005; 65 (23): 108307.
  • 34
    Kao CF, Chen SY, Chen JY, et al. Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein. Oncogene 2004; 23 (14): 247283.
  • 35
    Otsuka M, Kato N, Lan K, et al. Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability. J Biol Chem 2000; 275 (44): 3412230.
  • 36
    Honda M, Kaneko S, Shimazaki T, et al. Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells. Hepatology 2000; 31 (6): 13519.
  • 37
    Ray RB, Meyer K, Ray R. Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 1996; 226 (2): 17682.
  • 38
    Ray RB, Steele R, Meyer K, et al. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 1997; 272 (17): 109836.
  • 39
    Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004; 85 (Part 9): 2485502.
  • 40
    Prikhod'ko EA, Prikhod'ko GG, Siegel RM, et al. The NS3 protein of hepatitis C virus induces caspase-8-mediated apoptosis independent of its protease or helicase activities. Virology 2004; 329 (1): 5367.
  • 41
    Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437 (7062): 116772.
  • 42
    Barber GN. Host defense, viruses and apoptosis. Cell Death Differ 2001; 8 (2): 11326.
  • 43
    Disson O, Haouzi D, Desagher S, et al. Impaired clearance of virus-infected hepatocytes in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2004; 126 (3): 85972.
  • 44
    Chisari FV. Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepatology 1995; 22 (4 Part 1): 131625.
  • 45
    Gilles PN, Fey G, Chisari FV. Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice. J Virol 1992; 66 (6): 395560.
  • 46
    Dunsford HA, Sell S, Chisari FV. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res 1990; 50 (11): 34007.
  • 47
    Hildt E, Saher G, Bruss V, et al. The hepatitis B virus large surface protein (LHBs) is a transcriptional activator. Virology 1996; 225 (1): 2359.
  • 48
    Meyer M, Caselmann WH, Schluter V, et al. Hepatitis B virus transactivator MHBst: activation of NF-kappa B, selective inhibition by antioxidants and integral membrane localization. EMBO J 1992; 11 (8): 29913001.
  • 49
    Pasquinelli C, Bhavani K, Chisari FV. Multiple oncogenes and tumor suppressor genes are structurally and functionally intact during hepatocarcinogenesis in hepatitis B virus transgenic mice. Cancer Res 1992; 52 (10): 28239.
  • 50
    Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J Virol 2004; 78 (23): 1272534.
  • 51
    Arbuthnot P, Capovilla A, Kew M. Putative role of hepatitis B virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways. J Gastroenterol Hepatol 2000; 15 (4): 35768.
  • 52
    Jung MC, Spengler U, Schraut W, et al. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol 1991; 13 (3): 3107.
  • 53
    Stemler M, Weimer T, Tu ZX, et al. Mapping of B-cell epitopes of the human hepatitis B virus X protein. J Virol 1990; 64 (6): 28029.
  • 54
    Soussan P, Garreau F, Zylberberg H, et al. In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA. J Clin Invest 2000; 105 (1): 5560.
  • 55
    Soussan P, Tuveri R, Nalpas B, et al. The expression of hepatitis B spliced protein (HBSP) encoded by a spliced hepatitis B virus RNA is associated with viral replication and liver fibrosis. J Hepatol 2003; 38 (3): 3438.
  • 56
    Pietschmann T, Lohmann V, Rutter G, et al. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J Virol 2001; 75 (3): 125264.
  • 57
    Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7 (8): 92733.
  • 58
    Dandri M, Burda MR, Torok E, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 2001; 33 (4): 9818.
  • 59
    Kim KH, Seong BL. Pro-apoptotic function of HBV X protein is mediated by interaction with c-FLIP and enhancement of death-inducing signal. EMBO J 2003; 22 (9): 2104116.
  • 60
    Marusawa H, Hijikata M, Chiba T, Shimotohno K. Hepatitis C Virus Core Protein Inhibits Fas- and Tumor Necrosis Factor Alpha-Mediated Apoptosis via NF-kappa B Activation. J Virol 1999; 73 (6): 471320.
  • 61
    Park K-J, Choi S-H, Choi D-H, et al. Hepatitis C Virus NS5A Protein Modulates c-Jun N-terminal Kinase through Interaction with tumor necrosis factor receptor-associated factor 2. J Biol Chem 2003; 278 (33): 307118.
  • 62
    Shirakata Y, Koike K. Hepatitis B Virus X protein induces cell death by causing loss of mitochondrial membrane potential. J Biol Chem 2003; 278 (24): 220718.
  • 63
    Korenaga M, Wang T, Li Y, et al. Hepatitis C Virus core protein inhibits mitochondrial electron transport and increases Reactive Oxygen Species (ROS) production. J Biol Chem 2005; 280 (45): 374818.
  • 64
    Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 2001; 98 (17): 9599604.
  • 65
    Chou A-H, Tsai H-F, Wu Y-Y, et al. Hepatitis C virus core protein modulates TRAIL-mediated apoptosis by enhancing bid cleavage and activation of mitochondria apoptosis signaling pathway. J Immunol 2005; 174 (4): 21606.
  • 66
    Terradillos O, De La Coste A, Pollicino T., et al. The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver. Oncogene 2002; 21 (3): 37786.
  • 67
    Marusawa H, Matsuzawa S, Welsh K, et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 2003; 22 (11): 272940.